ITEM 8.01  OTHER EVENTS
On October 15, 2021, Revance Therapeutics, Inc. (the "Company") announced that
the United States (U.S.) Food and Drug Administration (the "FDA") has issued a
Complete Response Letter ("CRL") regarding the Company's Biologics License
Application (the "BLA") for DaxibotulinumtoxinA for Injection, for the treatment
of moderate to severe glabellar (frown) lines.
In a communication received by the Company on October 15, 2021, the FDA
indicated it is unable to approve the BLA in its present form and indicated that
there are deficiencies related to the FDA's onsite inspection at the Company's
manufacturing facility. The Company plans to request a Type A meeting with the
FDA as soon as possible to address the deficiencies raised.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses